Serono launches new autoinjector device

Swiss biotech company Serono has launched the Rebiject II autoinjector, a device specifically designed to make self-injection of Rebif (interferon β-1a) more convenient for multiple sclerosis (MS) patients.

Rebiject II is specifically designed for use with the Rebif prefilled syringe. It provides several advantages over the previous autoinjector:

• Fewer steps are needed to inject - no need to remove the plunger from the prefilled syringe

• An adjustable needle depth regulator to allow the injector be tailored to each patient

• A visual signal to show patients that the injection has been fully delivered

• A safety mechanism to minimise the chance of accidental activation that could result in loss of medication

• Better design making it easier for MS patients to handle, with a square, non-rolling, non-slip rubber grip.

A study conducted in 115 patients with MS on Rebif therapy showed that 71% found the new Rebiject II was better than their previous injection method. Patient feedback indicated that injections were less painful, and that the Rebiject II was easier to use than the previous Rebiject mini autoinjector or manual injection.

'Rebiject II should make Rebif administration easier and help to support treatment compliance for multiple sclerosis patients,' said Franck Latrille, head of product development at Serono.

The new Rebiject II autoinjector is currently being launched in Europe and Canada as well as in certain countries of Asia, Latin America and the Middle East. It is expected to be available worldwide by the end of 2004.